Information Provided By: 
Fly News Breaks for April 19, 2018
GWPH
Apr 19, 2018 | 12:19 EDT
Cantor Fitzgerald analyst Elemer Piros raised his price target for GW Pharmaceuticals to $205 and reiterates an Overweight rating on the shares after an FDA advisory committee voted 13-0 that the benefit-risk profile of cannabidiol is favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
